Related Experiment Video

Updated: May 18, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

New therapeutic challenges in advanced bladder cancer

Joaquim Bellmunt1, Daniel P Petrylak

  • 1Medical Oncology Service, Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.

Seminars in Oncology
|October 9, 2012
PubMed

Insights

Advanced bladder cancer treatment remains difficult, with poor survival rates despite chemotherapy. Novel therapies and a deeper understanding of tumor biology are crucial for developing effective, personalized treatments for urothelial cancer.

Area of Science:

  • Oncology
  • Urothelial Carcinomas
  • Cancer Therapeutics

Background:

  • Advanced bladder cancer treatment faces challenges, with suboptimal 5-year survival rates (5-20%) despite conventional cisplatin-based chemotherapy.
  • Limited progress in chemotherapy, including triplet regimens and dose-dense formulations, highlights the need for novel therapeutic strategies.
  • Current treatment paradigms require new options for both first- and second-line therapies, catering to both fit and unfit patient populations.

Purpose of the Study:

  • To review current challenges and advancements in treating advanced bladder cancer.
  • To explore novel therapeutic avenues, including new chemotherapeutic agents and targeted therapies.
  • To emphasize the importance of understanding tumor biology for personalized urothelial cancer treatment.

Main Methods:

  • Review of existing literature on advanced bladder cancer chemotherapy and novel therapeutic approaches.
  • Analysis of ongoing Phase II and III clinical trials for new chemotherapeutic and targeted agents.
  • Exploration of research focusing on tumor biology and tumorigenesis pathways.

Main Results:

  • Conventional chemotherapy shows limited long-term efficacy for advanced bladder cancer.
  • Targeted therapies have not yet demonstrated significant benefit, but numerous agents are under investigation.
  • Advances in understanding tumor biology offer potential for future personalized treatment strategies.

Conclusions:

  • Novel therapeutic strategies are urgently needed for advanced bladder cancer.
  • Ongoing research into new agents and a better understanding of tumor biology are critical.
  • Personalized treatment approaches based on individual patient tumor characteristics hold promise for improving outcomes in urothelial cancer.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.